Explore this article's sources with AI
Follow PeptideMethods on Google
SOUL recurrent events: oral semaglutide
A secondary SOUL analysis counted first and later cardiovascular events. We separate its total-event result from the parent trial's primary endpoint.
Why we wrote this. A recurrent-event analysis can sound like a new trial. We separate its cumulative event-burden result from SOUL's confirmatory first-event endpoint and disclose the exploratory limits.
In this article (6 sections)
A prespecified secondary analysis of SOUL counted first and later major cardiovascular events during the same randomized trial. Among 9,650 adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the oral semaglutide group had 683 three-point major adverse cardiovascular events, compared with 791 in the placebo group. The estimated ratio of cumulative mean event burden was 0.86 (95% confidence interval 0.76 to 0.97; p = 0.01)[1].
This is not a second randomized trial. It reanalyzes SOUL to include recurrent events after a participant's first nonfatal heart attack or stroke. The parent trial's confirmatory question concerned time to a first event. Its result was 579 of 4,825 participants (12.0%) with oral semaglutide and 668 of 4,825 (13.8%) with placebo, a hazard ratio of 0.86[2].
The secondary analysis used the parent SOUL population
SOUL was a double-blind, placebo-controlled, event-driven phase 3b trial at 444 centers in 33 countries. It randomized 4,825 people to once-daily oral semaglutide and 4,825 to placebo, both alongside standard care. Median follow-up was 49.5 months. Participants had type 2 diabetes plus established atherosclerotic cardiovascular disease, chronic kidney disease, or both[1]. The registry records randomized parallel assignment and masked participants, clinicians, investigators and outcome assessors[3].
Three-point MACE combined cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. An independent committee adjudicated events. The recurrent-event analysis followed the intention-to-treat principle and used in-trial data regardless of adherence or background-medication changes. The authors call this a treatment-regimen estimand: it estimates the effect of assignment to the treatment strategy, rather than the effect only while tablets were being taken.
Total events favored oral semaglutide
The 683 events with oral semaglutide comprised 579 first and 104 subsequent events. The 791 with placebo comprised 668 first and 123 subsequent events[1]. Across both groups, 1,247 of 1,474 events were first events and 227 were subsequent events. Counting later events therefore added information about 15.4% of the observed cardiovascular burden.
The mean ratio is not a hazard ratio and is not an individual probability. The investigators used a Ghosh-Lin model to estimate the cumulative mean number of events over follow-up, while treating noncardiovascular death as a competing terminal event. A mean ratio of 0.86 means the modeled cumulative event burden was 14% lower in the assigned semaglutide group. It does not mean every participant's risk fell by 14%, and raw event counts cannot show how many distinct people had a recurrent event.
A separate analysis added noncardiovascular death to three-point MACE. It counted 910 total events with oral semaglutide and 1,048 with placebo, for a mean ratio of 0.87 (95% CI 0.79 to 0.95; p = 0.004)[1]. That combined analysis was post hoc, unlike the prespecified principal recurrent-event analysis, so it should be treated as supportive and exploratory.
Later-event estimates were less precise
The supplementary sequence analysis reported 83 second events with oral semaglutide and 97 with placebo. Its hazard ratio was 0.85, but the 95% CI ranged from 0.63 to 1.13 and p was 0.26. Third events numbered 16 and 22, with a hazard ratio of 0.72 and a still wider 95% CI from 0.38 to 1.37[1]. Those estimates do not independently establish fewer second or third events. The total-event model is the main result of this paper.
Participants who had recurrent events tended to be older and to have longer diabetes duration, higher HbA1c, more inflammation and more prior heart attack or stroke than participants without an event. Those comparisons describe risk concentration inside the trial. They do not identify which characteristic caused recurrence or show that semaglutide's effect differed across those characteristics.
Safety came from the parent trial
The secondary paper did not run a new adverse-event comparison. It repeated that adverse events led to treatment discontinuation in 749 participants assigned oral semaglutide (15.5%) and 559 assigned placebo (11.6%)[1]. In the parent report, serious adverse events occurred in 47.9% and 50.3%, respectively, while gastrointestinal disorders occurred in 5.0% and 4.4%[2]. These group-level results do not predict an individual's tolerability.
Sponsor involvement and analysis limits matter
Novo Nordisk funded SOUL and the open-access fee. The company maintained the clinical database and performed the statistical analyses. The full report says the sponsor and academic steering committee shared roles in trial design, conduct, data collection, analysis and interpretation; the sponsor also participated with the authors in manuscript preparation, review and the submission decision. Several authors were Novo Nordisk employees and shareholders, while many others reported industry relationships[1].
The analysis has further limits. SOUL was powered for the first-event primary outcome, not treatment differences in recurrent events. The recurrent analyses were exploratory, with no adjustment for multiple statistical tests. They did not determine whether an event happened during active treatment exposure, and the investigators lacked data on cardiovascular medicines taken between first and later events. The supplementary event-order model also did not enforce that a first event must precede a second in its risk sets.
What the recurrent-event result adds
The parent SOUL publication established fewer first three-point MACE events with oral semaglutide in this high-risk population[2]. The new analysis asks a narrower question and shows a similar relative pattern after later events are included. It does not establish primary prevention, apply to lower-risk adults, compare oral with injectable semaglutide, or prove a separate effect on each component of the composite. Our semaglutide evidence overview places this result alongside other populations and formulations.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Was this a new randomized trial?
No. It was a prespecified secondary analysis of the existing 9,650-participant SOUL randomized trial. The new paper counted first and subsequent cardiovascular events rather than recruiting or randomizing another population.
What did the recurrent-event analysis find?
There were 683 first and subsequent three-point MACE events with oral semaglutide and 791 with placebo. The estimated ratio of cumulative mean event burden was 0.86, with a 95% confidence interval from 0.76 to 0.97.
What was included in three-point MACE?
The composite included cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. The recurrent-event analysis counted later qualifying events after a participant's first nonfatal event.
Did the paper prove fewer second and third events separately?
No. The separate second- and third-event estimates had wide confidence intervals that included no difference. The paper's main finding came from the model that combined first and subsequent events into cumulative event burden.
Sources
- [1]Marx et al. First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes (2026; PMID 43013292; full text)Tier 1 · primary↩
- [2]McGuire et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (2025; PMID 40162642)Tier 1 · primary↩
- [3]ClinicalTrials.gov record for SOUL (NCT03914326)Tier 1 · primary↩
No revisions yet. First published .